Efficacy Screening Of Antibody-Drug-Conjugates By Surface Plasmon Resonance

By Helen Hsu, Jeff Carroll, Jason Ramsay, Lisa McDermott, Agata Burzawa, and Elinor George

GettyImages-2152418334 3D Rendering Of ADCs

The unique target-specific binding of ADCs allows targeted delivery of cytotoxic small molecules to cancer cells and thus expands the therapeutic window. Prior to deploying ADCs to in vivo systems, the characteristic of in vitro efficacy must be evaluated for candidate selection.

In vitro efficacy evaluation of an ADC provides valuable insights for preliminary candidate selection at the preproduction development phase to maximize therapeutic outcomes in the clinic. Assays including cytotoxicity, antigen binding affinity, internalization, and Fc-mediated toxicity are extensively assessed.

Rapid screening of ADC affinity using surface plasmon resonance (SPR) provides preliminary efficacy data in comparison of antigen binding affinity of ADC with selected linkers and payloads to the non-conjugated antibody.

access the Poster!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Biosimilar Development? Subscribe today.

Subscribe to Biosimilar Development X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Biosimilar Development